08 . 04 .2021
Press release
Galderma announces publication of phase 2b trial results demonstrating the rapid and long-lasting benefits of nemolizumab in clinical trial subjects with uncontrolled atopic dermatitis
10 . 03 .2021
Press release
Galderma online survey reveals almost two thirds of rosacea patients* are experiencing worsening of signs and symptoms related to essential COVID-19 mask wearing
04 . 03 .2021
Press release
Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe
04 . 02 .2021
Press release
Galderma receives FDA approval for Restylane® Defyne for chin augmentation
18 . 11 .2020
Press release
Galderma launches Dysport® in China for treatment of glabellar lines
17 . 11 .2020
Press release
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
09 . 10 .2020
Press release
Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting
10 . 06 .2020
Press release
Galderma global research reveals struggles of people with rosacea and psoriasis of the face experiencing a lack of control and impact on mental wellbeing
12 . 05 .2020
Press release
Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport® (abobotulinumtoxinA) Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Year